Psilocybin in alcohol use disorder and comorbid depressive symptoms
/Depression after alcohol detox is a big risk factor for relapse to drinking, so this study looked at psychedelic assisted psychotherapy with psilocybin (the active ingredient in magic mushrooms) to see if they could improve outcomes. Two groups were randomized; one group received a 25mg dose and the other got a placebo of 1mg which is an inactive microdose. A few different outcome measures were different between the groups: number of drinking days, craving scores, and relapse rates were all better in the 25mg group, suggesting psilocybin has a genuine effect in facilitating staying quit from drinking. Still, this is a small study, enrolling only 30 individuals, so as they say, more research needs to be done. Check out the link below for the full article. While psilocybin is still not available for medical use in the United States, it will likely be in the coming years at which point it’s worth considering. For now, ketamine assisted psychotherapy remains the only medically available psychedelic, which also has robust anti-addiction properties; confusingly, it also sometimes precipitates a ketamine use disorder, so it’s worth closely considering the risks and benefits, and working with an experienced clinician.
Luquiens A, Belahda D, Graux C, Igounenc N, Serrand C, Rochefort P, et al. Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial. Addiction. 2025. https://doi.org/10.1111/add.70152
full text: https://onlinelibrary.wiley.com/doi/10.1111/add.70152